Inmed (IN:CSE) CEO’s Letter to Shareholders & Corporate Presentation
Letter from President and CEO
Dear Shareholder,
As the new President and CEO at InMed, I’m reaching out to you to provide you with my impressions after my first 3 weeks at the company, and to give you some insight into what I see as the operational priorities for InMed moving forward.
As I have become more familiar with the rationale and science behind InMed’s technology I have had two key observations: I was impressed with the level of detail and science behind the process of identifying new potential candidates, and I was struck by the number of potential opportunities that were available to InMed within the cannabinoid space.
I believe InMed’s process of drug discovery is quite sophisticated, and much more advanced than what is being used by most companies developing natural products, and in particular compared to other pharma companies developing cannabinoids. This is promising as this means that our products have been rationally targeted and designed and therefore should be both effective and potent. The potential number of indications in which InMed could be active is numerous. Cannabinoids have been shown to play a role in a number of human physiological systems, and the potential to mediate a therapeutic effect has been observed in multiples therapeutic areas including infectious diseases, metabolic diseases, respiratory diseases, ocular diseases, oncology and dermatology. The breadth of indications available with our technology presents a wealth of opportunity for InMed, however initially, to utilize our resources effectively, we will focus our development portfolio on two indications, epidermolysis bullosa (EB) and glaucoma.
Epidermolyis bullosa is an orphan disease mostly commonly seen in children and characterized by patients with very fragile skin. Even a slight brushing against a patient’s skin can cause severe blistering and redness, and many of these children spend most of their life in bandages. Currently the only treatment option for patients with EB is the same as that for the treatment of burns. We believe there is a significant opportunity for a new product that has been developed specifically for EB. INM-750 was designed specifically to address both the underlying cause of EB, and to treat the most commons symptoms. We intend to start clinical trials with INM-750 in EB in 2016.
Glaucoma is an eye disease that is one of the leading causes of blindness in the developing world. It is generally caused by high blood pressure in the eye (high intraocular pressure or IOP) which puts pressure on the optic nerve resulting in blindness. Currently, all the approved medications for glaucoma work by lowering IOP. Physicians are seeking novel medications that have a different mechanism of action to treat those patients that don’t respond well to current medications. InMed is developing INM-085 which has been designed not only to provide a new mechanism to lower IOP but also to provide a neuroprotective effect to the optic nerve. Glaucoma is a significant opportunity which currently represents a $5.6 B market globally. We plan to initiate our clinical trials in glaucoma in late 2016
I am quite excited about the science and technology at InMed and about the potential for our development candidates INM-750 and INM-085 to provide a meaningful contribution to patients. I have enclosed for you a copy of our revised company presentation that outlines our strategy for moving forward. This will provide you with much more detail about out platform, and the potential of our products.
http://www.inmedpharma.com/i/pdf/presentations/InMed-Presentation-Oct2015.pdf
Best regards,
Paul Brennan,
President & CEO
- Published in Blog, Business, Life Sciences, Medical Marijuana
Affinor Growers announces senior management changes
Vancouver (Canada), October 2, 2015 – Affinor Growers (CSE:AFI, OTC:RSSFF, Frankfurt:1AF) (“Affinor” or the “Corporation), a diversified agriculture and biotechnology company with proprietary vertical farming systems, announces that the Board of Directors have appointed Mr. Jarrett Malnarick as interim CEO and Mr. Mark T Brown as CFO. The management changes reflect the plans for the company’s next phases of growth. Mr. Sebastien Plouffe and Mr. Hugh Bowman have both resigned from their positions as of today. Mr. Pierre C Miron, the former CFO has also resigned as CFO and Director and Affinor has concluded a termination agreement with him.
The board would like to thank Mr. Plouffe, Bowman and Miron for their guidance, leadership and input during the early days of Affinor’s development. Mr. Sebastien Plouffe, former President and CEO, comments: “I became Affinor’s CEO in 2013 and since then I grew the company and helped significantly to build and do something good for the shareholders. For personal reasons, it’s time for me to leave. I believe in the success of the Company and the changes in the management are positive. I will continue to support the Company and I wish all the best to Affinor.”
Mr. Jarrett Malnarick has been appointed as the interim CEO. He has been Affinor’s COO for the past year and a half and is knowledgeable about the technology and company direction. Mr. Malnarick is known for his hands on approach and has over 15 years of experience in product development, retail logistics, operational systems development, effective team building and regulatory compliance. Mr. Malnarick has held a number of executive positions and has earned a Bachelor of Science from the University of Victoria.
Mr. Malnarick, Affinor’s new interim CEO, comments: “I am honored to have been selected for the interim CEO and feel a strong sense of commitment to Affinor, the directors and investors. I am excited to work with the board and staff to deliver on the priorities set for Affinor.”
Mr. Mark T. Brown B. Comm. CPA, CA, is the President of Pacific Opportunity Capital Ltd., in Vancouver B.C. Mr. Brown has assisted in the successful establishment of several private and public companies. In the public company sector, Mr. Brown has played key roles in the success of several companies which his team at Pacific Opportunity has listed the TSXV, the TSX and the NYSE Mkt Exchanges. His corporate focus is merger and acquisition transactions, financing, strategic corporate planning, and corporate development. One of the companies founded by the team at Pacific Opportunity was built into a plus $500 million market capitalization entity and they have had many smaller success over the past 20 years.
Prior to joining Pacific Opportunity, Mr. Brown managed the financial departments of two TSE 300 companies, Miramar Mining Corp. and Eldorado Gold Ltd. Mr. Brown has a Bachelor of Commerce from the University of British Columbia and qualified as a Chartered Accountant in 1993, while working with PricewaterhouseCoopers in Vancouver. Mr. Brown’s family history includes having run large greenhouse operations near Vancouver for many years as Brown Brothers Florists and he looks forward to working with the team at Affinor in working to modernize these processes.
The main reasons ofthose changes are to improve efficiency of the Corporation and to reduce the burn rate. In that sense, the Corporation is also moving the office to Vancouver. The Quebec development project is still a priority and when the full financing will be in place, a special team will be hired specifically for the project. Regarding this project, negotiations are continuing in order to finance it with the right strategic partners in the industry. Affinor is also focusing on technology licensing opportunities, selling the equipment to strategic partners mainly in the food industry to demonstrate the quality of the products and the economic viability of the model.
The Corporation has also agreed to settle a total of $78,207 of debt relating to consulting fees and service fees to certain arm’s-length and non-arm’s-length parties by issuing an aggregate of 1,303,450 common shares of Affinor at a deemed price of six cents per share. Further, the Corporation has granted, in compliance with their option plan, hundred thousand incentive stock options to a consultant. Each option is exercisable into a common share of Affinor at ten cents per common share for a period of two years.
About Affinor Growers Inc.
Affinor Growers is a diversified publicly traded company on the Canadian Securities Exchange under the symbol (“AFI”). Affinor is focused on growing high quality crops such as romaine lettuce, spinach, strawberries. Affinor is committed to becoming a pre-eminent grower, using exclusive vertical farming techniques.
On Behalf of the Board of Directors
AFFINOR GROWERS INC.
“Jarrett Malnarick”
President & CEO
(604) 837-8688
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release
FORWARD LOOKING INFORMATION
This News Release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This News Release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
- Published in Affinor Growers
Amana (AMA:C) Congratulates IWS CEO on Canada Clean50 Award
Lynn Mueller, Founder and CEO of International Wastewater Systems Receives ‘Clean50’ Award
Amana Copper Ltd. (“Amana” or the “Company“) (CSE:AMA) would like to congratulate Mr. Lynn Mueller, Founder and CEO of International Wastewater Systems (“IWS”) on being recognized with a Canada Clean50 award (“Clean50”).
Canada’s Clean50 is an annual award offering recognition to Canada’s leaders in sustainability for their contributions over the prior two years. The Clean50 are selected from 16 diverse categories that transcend numerous industries, academia, different levels of government, thought leaders and advocates, and are based on accomplishments delivered over the prior two years.
Mr. Mueller was one of two recipients in the ‘Renewable Energy Generation’ category and received the award at the Clean50 Summit held in Toronto on September 23rd, 2015.
Mr. Mueller’s vision for green energy innovation has established IWS as a world leader in wastewater heat recovery systems. IWS technology provides simple and direct heat exchange from untreated waste water, resulting in the most energy-saving, cost-effective and environmentally friendly solutions for heating, cooling and hot water for any building, residential, commercial or industrial. IWS systems are currently being deployed worldwide for public and private sector clients.
Amana and IWS have signed a definitive agreement (see press release dated September 9th, 2015) pursuant to which Amana will acquire 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the issued and outstanding common shares of IWS subject to shareholder, regulatory and CSE approvals.
About IWS
International Wastewater Systems was founded by a team of technical and engineering professionals with over 100 years of combined experience in the heating, ventilating and geo-exchange industries. With a focus on wastewater heat recovery we are committed to manufacturing quality products that positively impact our environment, saving resources and unnecessary expense for heating and cooling.
For more info: www.sewageheatrecovery.com/
Aurora Announces Completion of Pre-License Assessments by Health Canada, Receipt of Production License for Building Number 3 and other Updates
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Oct. 1, 2015) – Aurora Cannabis Inc. (CSE:ACB)(FRANKFURT:21P)(WKN:A1C4WM)(OTCQB:ACBFF) (“Aurora” or the “Company”) is pleased to announce that on Friday, September 25, 2015, Health Canada inspectors from the Regions and Programs Bureau (“RAPB”) completed their latest assessments in response to three active section 29 license amendment applications. The assessment visit commenced on September 22, 2015.
On the same day, Aurora received approval for its Building Number 3 Production license under the Marihuana for Medical Purposes Regulations (“MMPR”). Aurora’s entire facility is now approved to produce dried medical cannabis.
Aurora anticipates receiving further news regarding the additional section 29 license amendment applications including the Cannabis Oil Production License and the Sale of Dried Marijuana License.
Terry Booth, CEO, commented: “Getting the building 3 confirmation so quickly after the inspection is a fantastic sign. We are looking forward to the issuance of our sales license and extraction license so we can provide Canadians high quality medical cannabis produced to the Aurora Standard.”
Australis Holdings LLP, a 50{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} subsidiary of Aurora, continues with the engineering and design on the Bellingham project. The preliminary drawings have been received and are being reviewed. Washington regulators announced plans to begin Phase 2 of their medical cannabis program including to once again accept license applications on October 12, 2015, for the first time since 2012.
About Aurora Cannabis Inc.
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada. Aurora’s wholly-owned subsidiary, Australis Capital Inc., seeks to be an active participant in the U.S. Cannabis market. Aurora is trading on the Canadian Securities Exchange under the trading symbol “ACB”.
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
The CSE, securities commission or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.
Aurora Cannabis Inc.
Nilda Rivera
Investor Relations
Toll Free: 1-844-928-7672
nilda@auroramj.com
www.auroramj.com
- Published in Aurora Cannabis